Logo
ISO 9001:2000
Menu Arrow
Menu Top
Menu Arrow
Menu Top
Menu Arrow
ISO Certified

Self-Administered Drug Exclusion Directive

 

 

Article for Self-Administered Drug Exclusion Directive - Medical Policy Article (A23213)

 

Contractor Information

 

Contractor Name

National Government Services, Inc.  

Contractor Number 

00308 

Contractor Type 

FI 

Article Information

 

Article ID Number

A23213 

Article Type

SAD Exclusion Article

Key Article 

No

Article Title

Self-Administered Drug Exclusion Directive - Medical Policy Article 

AMA CPT / ADA CDT Copyright Statement 

CPT codes, descriptions and other data only are copyright 2007 American Medical Association (or such other date of publication of CPT). All Rights Reserved. Applicable FARS/DFARS Clauses Apply. Current Dental Terminology, (CDT) (including procedure codes, nomenclature, descriptors and other data contained therein) is copyright by the American Dental Association.© 2002, 2004 American Dental Association. All rights reserved. Applicable FARS/DFARS apply.

 

Primary Geographic Jurisdiction

Connecticut
Delaware
New York - Entire State
 

Secondary Geographic Jurisdiction 

Connecticut
Delaware
New York
 

Original Article Effective Date 

09/01/2004

Article Revision Effective Date 

11/14/2007

Article Text 

Self-Administered Drug Exclusion Directive

This article replaces the one that was posted to the National Government Services, Inc. Web site on
07/25/2007. This listing will only have noncovered determinations per the Centers for Medicare & Medicaid Services (CMS) requirement. This listing will be updated as necessary when new decisions are made on excluded self-administered drugs.

The
CMS issued the Self-Administered Drug Exclusion Program Memorandum, Change Request 2200, on August 1, 2002. The directive instructed each Medicare carrier to establish a process, modeled along CMS guidelines, to determine the exclusion from Medicare coverage of those drugs, which were deemed usually self-administered, even though they may have been previously covered under “incident to” provisions. This notification is National Government Services, Inc.’s response to the CMS instructions. The details of the Medicare process can be viewed at http://www.cms.hhs.gov/transmittals/downloads/AB02139.pdf External PDF under Reference File AB-02-72. The list of drugs identified includes those which are administered “incident to” a physician’s service, and more importantly, those drugs that will not be covered or will no longer be covered “incident to” a physician service, because they have been deemed by National Government Services, Inc. to be “usually self-administered” by the patients who take them.

The Process

Reliable statistical information on the extent of self-administration by the patient may not always be available. In the absence of such data, drugs delivered intravenously should be presumed to be not usually self-administered by the patient. Absent evidence to the contrary, drugs delivered by intramuscular injection may be presumed to be not usually self-administered by the patient, although the depth and nature of the particular intramuscular injection may be considered in applying this presumption. Absent evidence to the contrary, drugs delivered by subcutaneous injection will be presumed to be self-administered by the patient, although National Government Services, Inc. will consider other factors such as acuteness of condition and frequency and duration of injection.

For the purposes of applying this exclusion, the term “usually self-administered” means self-administered more than 50 percent of the time for all Medicare beneficiaries who receive the drug, while not inpatients in a hospital, skilled nursing facility (SNF) or other facility. If a drug is self-administered more than 50 percent of the time, the drug is excluded from coverage, and National Government Services, Inc. will make no payment for it. The determination of exclusion or coverage is on a drug-by-drug basis, and not on a beneficiary-by-beneficiary basis.

National Government Services, Inc. arrived at a single determination for each drug by reviewing each indication and its route of administration for that indication. The relative contribution for each indication to the total use of that drug (i.e., weighted average) was obtained in order to arrive at the overall status of administration. Hypothetically, if a drug has three indications, and for the first indication which makes up 30 percent of the use, the drug is usually self-administered, while the second and third indications, which make up collectively 70 percent of the use, the drug is not usually self-administered, then the drug would be determined overall to be not usually self-administered. Consequently, this drug would be payable incident to a physician’s service under Medicare self-administered exclusion provisions. Conversely, if a different drug has two indications, and for the first indication, which comprises 60 percent of the use, it is usually self-administered, and for the remaining 40 percent use of the drug, it is not usually self-administered, then the overall determination would be that the drug is usually self-administered. In this case, the drug would be excluded from coverage under Medicare self-administered guidelines.

For a certain injectable drug, it is “apparent on its face value” by the nature of the condition(s) for which the drugs is administered, or the usual course of treatment for specific conditions (chronic vs. acute), what the usual mode of administration is. For example, Medicare deems a treatment course of injections lasting less than two weeks, regardless of frequency of injection or route, as acute. It would be unlikely that the patient would self-administer the drug. Therefore, the drug would be covered under Medicare self-administered exclusion provisions. For other injectable medications, it may be apparent by the usual and customary route of administration that the drug would be covered (IV, IM medications).

Definitions/Clarifications

In applying this exclusion process, National Government Services, Inc. utilized the following definitions and clarifications:

The term usually, as applied in this decision means more than 50 percent of the time for all Medicare beneficiaries who are within the National Government Services, Inc. jurisdiction, who are not facility inpatients and to whom the drug is administered. Consequently, a drug is “usually” self-administered when more than 50 percent of the time the beneficiary injects him or herself.

Self-administered means administered by the patient to him or herself, and does not include administered by spouses, nursing aides, allied health professionals, or physicians.

Incident to the provider’s service means that the provider or nurse practitioner be personally present for the administration of the drug.

Medicare will only pay for the drug if the drug is administered incident to a provider service,
AND it has already been deemed usually not self-administered.

This coverage does not establish a universal Medicare prescription coverage plan.

This coverage process only applies to the consideration of whether a drug is usually self-administered, and not to whether it is medically necessary. Drugs that are deemed not to be usually self-administered may still not be covered/payable if they do not meet all medical necessity criteria.

Places of service appropriate for this benefit are office (11) and home (12) if the physician or qualified non-physician practitioner is present, or the outpatient hospital (22). Inpatient hospital administration of drugs is not included in this benefit, and is not included in the determination of whether or not a drug is self-administered.

The physician must purchase the drug. If the drug is purchased by the beneficiary and then administered by the physician, the drug will not be covered.

Drugs administered by a home health agency nurse are not reimbursable under these provisions.

Evidentiary criteria utilized in arriving at National Government Services Inc.’s specific determinations include, but not exclusively or collectively, peer reviewed medical literature, standards of medical practice, evidence-based practice guidelines, FDA-approved label, and package inserts.

Drugs administered other than by injection (i.e., topically, or as suppositories or via inhalers) are assumed to be self-administered and are not covered under this benefit.

Implementation

The publication date of this list and any subsequent additions to the list begins a 45-day notice period. National Government Services, Inc., during this time, will maintain current existing medical review and payment procedures. After the 45-day period, National Government Services, Inc. will deny payment for “Not Covered” drugs on this list, subject to the terms of this notice. The list will be regularly reviewed and updated.

Appeals/Comments

For a particular drug, if a beneficiary’s claim is denied because the drug is subject to the “self-administered drug” exclusion, the beneficiary may appeal the denial. In cases where National Government Services, Inc. has deemed a drug usually self-administered, and therefore not covered, and an individual beneficiary appeals the denial on grounds that he or she does not self-administer the drug, it should not be assumed that the National Government Services, Inc. decision would be overturned, once the appeal is made. An Advance Beneficiary Notice (
ABN) is not required in this case since this a “benefit category” denial (i.e., a denial based on the fact that there is no benefit category under which the drug may be covered) and not a denial based on medical necessity. The physicians or providers may bill the beneficiary for an excluded drug. Providers, billing for an excluded drug, may wish to provide beneficiaries with a Notice of Exclusion from Medicare Benefits (NEMB) (form CMS-20007), available on the CMS Web site at: http://www.cms.hhs.gov/BNI/Downloads/CMS20007English.pdf External PDF . Additionally, providers accepting assignment may appeal a denial under provisions found in Publication 100-04, Medicare Claims Processing Manual, Chapter 29, Section 310. Providers, as part of an appeal, should submit to National Government Services, Inc. practice pattern evidence and/or scientific literature to support the potential overall reversal of National Government Services Inc.’s position on a particular drug. A hospital may also appeal a denial under Section 3781.2 of the Medicare Intermediary Manual to its fiscal intermediary.

Comments may be directed to:

National Government Services, Inc.
Medical Policy Unit (
Maine office)
Routing Code: ME0105-E070
P.O. Box 4767
Syracuse, NY 13221-4767
Attn: Martha Milton

Reference: Change Request 2200, Transmittal AB-02-072, CR 2311, Transmittal AB-02-139

Coverage Topic 

Prescription Drugs
 

Coding Information

 

Revenue Codes: 

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory; unless specified in the article services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the article should be assumed to apply equally to all Revenue Codes.

Revenue codes will be listed in the appropriate drug coverage article.

0024 - The Revenue code, Form Locator (FL) 42, Record Type (RT) 60, field 5), (SV201), must contain revenue code 0024. This code indicates that this claim is being paid under the
PPS. This revenue code can appear on a claim only once. CMS Publication 100-04, Medicare Claims Processing Manual, Chapter 3, Section 140.3

When coding
PPS bills for ancillary services associated with a Part A inpatient stay, the traditional revenue codes will continue to be shown in FL 42, e.g., 0250 - Pharmacy, 042x - Physical Therapy, in conjunction with the appropriate entries in Service Units, FL46 and Total Charges, FL47. CMS Publication 100-04, Medicare Claims Processing Manual, Chapter 3, Section 140.3.

Please note that not all revenue codes apply to every type of bill code. Providers are encouraged to refer to the Fiscal Intermediary Shared System (FISS) revenue code file for allowable bill types.

Similarly, not all revenue codes apply to each
CPT/HCPCS code. Providers are encouraged to refer to the FISS HCPCS file for allowable revenue codes.

Revenue codes only apply to providers who bill these services to the fiscal intermediary. Revenue codes do not apply to physicians, other professionals and suppliers who bill these services to the carrier.

 

Coding Table Information

 

CPT/HCPCS Codes - Table Format 

Code

Descriptor Generic Name

Descriptor Brand Name

Exclusion Effective Date

Exclusion End Date

Comments

J0135

INJECTION, ADALIMUMAB, 20 MG

Humira

06/02/2004

N/A

Non-acute subcutaneous (SC) injection by patient, weekly or every other week.

J0270

INJECTION, ALPROSTADIL, 1.25 MCG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF ADMINISTERED)

Caverject, Edex

06/02/2004

N/A

Usually self-injected by patient on an "as needed basis".

J0275

ALPROSTADIL URETHRAL SUPPOSITORY (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF ADMINISTERED)

Muse

06/02/2004

N/A

Supposistory.

J0630

INJECTION, CALCITONIN SALMON, UP TO 400 UNITS

Calcimar, Miacalcin

06/02/2004

N/A

Non-acute subcutaneous (SC) injection by patient, daily or every other day.

J1324

INJECTION, ENFUVIRTIDE, 1 MG

Fuzeon

12/28/2007

N/A

Non-acute subcutaneous (SC) injection by patient, twice daily.

J1438

INJECTION, ETANERCEPT, 25 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF ADMINISTERED)

Enbrel

06/02/2004

N/A

Non-acute subcutaneous (SC) injection by patient, usually twice a week.

J1595

INJECTION, GLATIRAMER ACETATE, 20 MG

Copaxone

06/02/2004

N/A

Self-administration; subcutaneous 20 mg/day.

J1675

INJECTION, HISTRELIN ACETATE, 10 MICROGRAMS

Supprelin

12/28/2007

N/A

Non-acute subcutaneous administration, usually once daily by patient.

J1815

INJECTION, INSULIN, PER 5 UNITS

Humalog, Humulin, Iletin, Insulin Lispo, Novo Nordisk, NPH, Pork Insulin, Regular Insulin, Ultralente, Velosulin, Humulin R, Iletin II Regular Port, Insulin Purified Pork, Relion, Lente Iletin I, Novolin R, Humulin R U-500

06/02/2004

N/A

Non-acute subcutaneous (SC) injection by patient, every day.

J1817

INSULIN FOR ADMINISTRATION THROUGH DME (I.E., INSULIN PUMP) PER 50 UNITS

Humalog, Humulin, Vesolin BR, Iletin II NPH Pork, Lantus, Lispro-PFC, Novolin, Novolog, Novolog Flexpen, Novolog Mix, Relion Novolin

06/02/2004

N/A

Non-acute chronic filling of pump by patient.

J1830

INJECTION INTERFERON BETA-1B, 0.25 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF ADMINISTERED)

Betaseron

06/02/2004

N/A

Non-acute subcutaneous (SC) injection by patient, usually every other day.

J2170

INJECTION, MECASERMIN, 1 MG

Increlex, Iplex

06/02/2004

N/A

Non-acute subcutaneous injection twice daily by patient.

J2354

INJECTION, OCTREOTIDE, NON-DEPOT FORM FOR SUBCUTANEOUS OR INTRAVENOUS INJECTION, 25 MCG

Sandostatin

06/02/2004

N/A

Usually self-administered injections two to four times daily, depending on the indication.

J2940

INJECTION, SOMATREM, 1 MG

Protropin

06/02/2004

N/A

Non-acute subcutaneous (SC) injection by patient, several time a week.

J2941

INJECTION, SOMATROPIN, 1 MG

Genotropin

06/02/2004

N/A

Non-acute subcutaneous (SC) injection by patient, several time a week.

J3030

INJECTION, SUMATRIPTAN SUCCINATE, 6 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF ADMINISTERED)

Imitrex

06/02/2004

N/A

Subcutaneous (SC) injection by patient at onset of symptoms (up to two times in a 24-hour period).

J3110

INJECTION, TERIPARATIDE, 10 MCG

Forteo

12/28/2007

N/A

Non-acute, subcutaneous (SC) injection into thigh or abdomen (lower stomach area) once a day by patient using multidose prefilled delivery device (FORTEO pen - contains 28 daily doses).

J3490

UNCLASSIFIED DRUGS

Byetta (exenatide)

12/28/2007

N/A

Non-acute subcutaneous (SC) injection by patient, within the 60-minute period before morning and evening meals.

J3490

UNCLASSIFIED DRUGS

Symlin (Pramlintide acetate)

12/28/2007

N/A

Non-acute subcutaneous (SC) injection by patient, immediately prior to major meals.

J3590

UNCLASSIFIED BIOLOGICS

Kineret

12/28/2007

N/A

Non-acute subcutaneous (SC) injection by patient, every day.

J3590

UNCLASSIFIED BIOLOGICS